Patents by Inventor Stefano Fiorucci

Stefano Fiorucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS
    Publication number: 20230357159
    Abstract: The present invention relates to compounds of formula (I), their pharmaceutical compositions and uses, in particular for the treatment and/or prevention of diseases mediated by bile acid receptors, FXR and GPBAR1, and cysteinyl leukotriene receptors (CysLTR).
    Type: Application
    Filed: August 4, 2021
    Publication date: November 9, 2023
    Inventors: Angela Zampella, Stefano Fiorucci
  • 6-SUBSTITUTED, 22-CYANO HYODEOXYCHOLANIC ANALOGUES AND USES THEREOF
    Publication number: 20230066156
    Abstract: The present invention relates to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of GPBAR1 mediated diseases.
    Type: Application
    Filed: December 9, 2020
    Publication date: March 2, 2023
    Inventors: Angela Zampella, Stefano Fiorucci
  • USE OF BACILLUS AMYLOLIQUEFACIENS AND/OR BACILLUS SUBTILIS FOR THE ENHANCEMENT OF ACTIVE PROBIOTIC COMPOSITIONS OR FOR THE ACTIVATION OF INACTIVE PROBIOTIC COMPOSITIONS, COMPOSITIONS THUS OBTAINED, AND RELATED METHOD
    Publication number: 20220160794
    Abstract: This invention relates to the use of Bacillus amyloliquefaciens and/or Bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions for use in the prevention and/or treatment of inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, indeterminate colitis and microscopic colitis, the compositions thus obtained, and a method for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions for use in the prevention and/or treatment of inflammatory bowel diseases, such as Crohn's disease, ulcerative colitis, indeterminate colitis and microscopic colitis.
    Type: Application
    Filed: April 29, 2020
    Publication date: May 26, 2022
    Inventor: Stefano FIORUCCI
  • Isoxazole as FXR receptor agonists
    Patent number: 11332450
    Abstract: The present invention related to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of FXR mediated diseases.
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: May 17, 2022
    Assignee: Bar Pharmaceuticals Societa' A Responsabilita' Limitata
    Inventors: Angela Zampella, Stefano Fiorucci
  • TREATMENT OF FIBROSIS USING FXR LIGANDS
    Publication number: 20210346400
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Application
    Filed: March 24, 2021
    Publication date: November 11, 2021
    Inventors: Stefano FIORUCCI, Roberto PELLICCIARI, Mark PRUZANSKI
  • Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
    Patent number: 11117926
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBARI mediated diseases.
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: September 14, 2021
    Assignee: BAR PHARMACEUTICALS S.R.L.
    Inventors: Angela Zampella, Stefano Fiorucci
  • Isoxazole as FXR Receptor Agonists
    Publication number: 20210269409
    Abstract: The present invention related to compounds of formula (I), to pharmaceutical compositions thereof and to their uses, in particular in the treatment and/or prevention of FXR mediated diseases.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 2, 2021
    Inventors: Angela Zampella, Stefano Fiorucci
  • Treatment of fibrosis using FXR ligands
    Patent number: 10987362
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: April 27, 2021
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • TREATMENT OF FIBROSIS USING FXR LIGANDS
    Publication number: 20200397803
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Application
    Filed: December 21, 2018
    Publication date: December 24, 2020
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • TREATMENT OF FIBROSIS USING FXR LIGANDS
    Publication number: 20200197414
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Application
    Filed: December 21, 2018
    Publication date: June 25, 2020
    Inventors: Stefano Fiorucci, Roberto Pelloclari, Mark Pruzanski
  • CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES
    Publication number: 20190352328
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.
    Type: Application
    Filed: August 1, 2019
    Publication date: November 21, 2019
    Inventors: Angela Zampella, Stefano Fiorucci
  • Cholane derivatives for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases
    Patent number: 10407462
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.
    Type: Grant
    Filed: May 28, 2015
    Date of Patent: September 10, 2019
    Assignee: BAR PHARMACEUTICALS S.R.L.
    Inventors: Angela Zampella, Stefano Fiorucci
  • Treatment of fibrosis using FXR ligands
    Patent number: 10258633
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 16, 2019
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 9763964
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: September 19, 2017
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • CHOLANE DERIVATIVES FOR USE IN THE TREATMENT AND/OR PREVENTION OF FXR AND TGR5/GPBAR1 MEDIATED DISEASES
    Publication number: 20170190731
    Abstract: The present invention relates to compounds having cholane scaffolds of formula (I), said compounds for use in the treatment and/or prevention of FXR and TGR5/GPBAR1 mediated diseases.
    Type: Application
    Filed: May 28, 2015
    Publication date: July 6, 2017
    Applicant: BAR PHARMACEUTICALS S.R.L.
    Inventors: Angela Zampella, Stefano Fiorucci
  • TREATMENT OF FIBROSIS USING FXR LIGANDS
    Publication number: 20170165277
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Application
    Filed: October 21, 2016
    Publication date: June 15, 2017
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • Treatment of fibrosis using FXR ligands
    Patent number: 9498484
    Abstract: The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
    Type: Grant
    Filed: March 14, 2005
    Date of Patent: November 22, 2016
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventors: Stefano Fiorucci, Roberto Pellicciari, Mark Pruzanski
  • Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
    Publication number: 20150359805
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 17, 2015
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions
    Patent number: 9090652
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: July 28, 2015
    Assignee: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski
  • Bile Acid Derivatives as FXR Ligands for the Prevention or Treatment of FXR-Mediated Diseases or Conditions
    Publication number: 20140057886
    Abstract: The present invention relates to compounds of formula (I): wherein R is hydrogen or alpha-hydroxy, the hydroxyl group in position 7 is in the alpha or beta position; and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof.
    Type: Application
    Filed: August 28, 2013
    Publication date: February 27, 2014
    Applicant: INTERCEPT PHARMACEUTICALS, INC.
    Inventors: Roberto Pellicciari, Stefano Fiorucci, Mark Pruzanski